Optimizing Dual-Time and Serial Positron Emission Tomography and Single Photon Emission Computed Tomography Scans for Diagnoses and Therapy Monitoring

IntroductionA region’s early and late tracer uptake activities, QE and QL, within a dual-time scan (i.e. using two frames) or in serial scans (as for monitoring therapeutic response), are popular quantitative diagnostic aids, especially in oncology. In this paper, maximum performance is sought from their joint use.Methods$$ {Q_{L} } \mathord{\left/ {\vphantom {{Q_{L} } {Q_{E} ^{n} }}} \right. \kern-\nulldelimiterspace} {Q_{E} ^{n} } $$ is introduced as a tumor marker with an empirical n. This generalizes traditional data weighting having n = 1 for QL/QE, the retention index (RI), with its associated % difference. Using patient data, iterative guessing finds an optimal n that maximizes a measure of diagnostic performance: D = (difference of normal and abnormal marker means)/(their combined SD), which may be computed from values of $$ {Q_{L} } \mathord{\left/ {\vphantom {{Q_{L} } {Q_{E} ^{n} }}} \right. \kern-\nulldelimiterspace} {Q_{E} ^{n} } $$, as well as of QL, QE, and RI each used alone. For 2-deoxy-2-[F-18]fluoro-d-glucose(FDG)-positron emission tomography (PET) dual-time protocols, another approach to optimization—selection of scan times—is investigated by simulations using the Sokolov model.ResultsA meta-analysis of 12 PET and single photon emission computed tomography (SPECT) studies with various tracers, cancers, and scan classes (dual-time or serial) finds ns from 0.5 to 1.1. The optimal D necessarily exceeds the best (or any) computed using QE, QL, or RI: negligibly to by as much as 0.6 (or 1.5). The increases in optimal receiver operating curve area (Az) over the best (or any) traditional marker range from negligible to 0.07 (or 0.4). QE alone usually has the lowest D and Az. Statistically significant performance improvement of $$ {Q_{L} } \mathord{\left/ {\vphantom {{Q_{L} } {Q_{E} ^{n} }}} \right. \kern-\nulldelimiterspace} {Q_{E} ^{n} } $$ over QE and QL is shown for most studies. Contrasting with an optimal n, another value n0 can also be found where D = 0. Occasionally, n0 can be close to 1, and RI then will have a small D and poor performance. Simulation with kinetic modeling of FDG dual-time scans for liver and liver metastases demonstrates worst and best scan times. Indicated for these imaging protocols are QE at very early cellular transport associated times and QL rather late when phosphorylation/dephosphorylation dominate. Benefits from choosing optimal times in dual-time protocols, especially in combination with choosing optimal ns, can be significant.ConclusionA protocol-dependent optimizing parameter n in an improved classification marker can easily be identified in a learning set of scans having normals and abnormals. Finding this parameter below 1.0 in most all studies suggests that a popularly used QL/QE may often overweight early activities. Additionally, QL/QE may sometimes be a poor marker choice and underestimate a protocol’s diagnostic capability. Subsequent use of the proposed $$ {Q_{L} } \mathord{\left/ {\vphantom {{Q_{L} } {Q_{E} ^{n} }}} \right. \kern-\nulldelimiterspace} {Q_{E} ^{n} } $$ in settings similar to that of the learning set gives improved diagnostic performance over traditional approaches, although by widely varying amounts. Additionally, a method of seeking optimal scan times is demonstrated and suggests significant gains in dual-time protocol performances are possible.

[1]  Wolfgang A Weber,et al.  Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Abass Alavi,et al.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  T. Shibasaki,et al.  Differentiating histologic malignancy of primary brain tumors: pentavalent technetium-99m-DMSA. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  T. Saga,et al.  Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  H. Sakahara,et al.  Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas , 2000, Cancer.

[6]  I. Sesterhenn,et al.  Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  M. Hata,et al.  FDG-PET scanning after radiation can predict tumor regrowth three months later. , 2003, International journal of radiation oncology, biology, physics.

[8]  P. Sinha,et al.  Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy , 2003, Nuclear medicine communications.

[9]  M. Ozaki,et al.  Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Z. Burak,et al.  Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer , 2006, Annals of nuclear medicine.

[11]  E. Hoffman,et al.  Noninvasive determination of local cerebral metabolic rate of glucose in man. , 1980, The American journal of physiology.

[12]  L M Hamberg,et al.  Simplified measurement of deoxyglucose utilization rate. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  John A. Swets,et al.  Evaluation of diagnostic systems : methods from signal detection theory , 1982 .

[14]  R. Hardoff,et al.  Uptake of gallium-67 citrate and [2-3H]deoxyglucose in the tumor model, following chemotherapy and radiotherapy. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Y. Inoue,et al.  Thallium‐201‐chloride thyroid scintigraphy to evaluate benign and/or malignant nodules usefulness of the delayed scan , 1982, Cancer.

[16]  D. Mankoff,et al.  Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. , 2002, Academic radiology.

[17]  R. Birdwell,et al.  Potential of Dual-Time-Point Imaging to Improve Breast Cancer Diagnosis with 18F-FDG PETKumar R, Loving VA, Chauhan A, et al (Univ of Pennsylvania, Philadelphia) J Nucl Med 46:1819–1824, 2005§ , 2007 .

[18]  V. Clark,et al.  Computer-aided multivariate analysis , 1991 .

[19]  T. A. Smith,et al.  FDG uptake, tumour characteristics and response to therapy: A review , 1998, Nuclear medicine communications.

[20]  Thomas K Lewellen,et al.  18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.